Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 02, 2023	Jul. 03, 2022	Jul. 02, 2023	Jul. 03, 2022
Segment Reporting Information [Line Items]
Revenues		$ 12,734	$ 27,742	$ 31,015	$ 53,402
Income from continuing operations before provision/(benefit) for taxes on income	[1]	2,269	11,447	8,539	20,497
Net gains/(losses) recognized during the period on equity securities	[2],[3]	135	(541)	(316)	(1,241)
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		91	69	183	125
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	316	317	626	655
Income from continuing operations before provision/(benefit) for taxes on income	[1],[4]	(2,871)	(3,384)	(5,605)	(5,812)
Inventory write-off		140	450	260	450
Other Business Activities [Member] | Reclassification Adjustment [Member]
Segment Reporting Information [Line Items]
Operating costs			(58)		(105)
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1]	(1,184)	(822)	(2,287)	(1,657)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1]	(387)	(82)	(550)	(269)
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1],[5]	(293)	(1,431)	(958)	(2,322)
Net gains/(losses) recognized during the period on equity securities			(539)		(1,200)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	12,418	27,425	30,389	52,748
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,418	27,425	30,389	52,748
Income from continuing operations before provision/(benefit) for taxes on income	[1]	$ 7,003	17,166	$ 17,939	30,557
Biopharma [Member] | Operating Segments [Member] | Reclassification Adjustment [Member]
Segment Reporting Information [Line Items]
Operating costs			$ 58		$ 105

[1] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $91 million in the second quarter of 2023 and $69 million in the second quarter of 2022, and $183 million in the first six months of 2023 and $125 million in the first six months of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $58 million of costs in the second quarter of 2022 and $105 million in the first six months of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.

[2] Reported in Other (income)/deductions––net. See Note 4.

[3] The net gains in the second quarter of 2023 include, among other things, unrealized gains of $202 million related to our investment in Cerevel Therapeutics Holdings, Inc. (Cerevel). The net losses in the first six months of 2023 include, among other things, unrealized losses of $276 million related to our investment in BioNTech. The net losses in 2022 included, among other things, unrealized losses of $432 million in the second quarter and $776 million in the first six months related to our investments in BioNTech and Cerevel.

[4] Other business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&D expenses in the periods presented. Earnings in the second quarter and first six months of 2023 include approximately $140 million and $260 million, respectively, of write-offs to Cost of sales of inventory related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used. Earnings in the second quarter and first six months of 2022 included a $450 million write-off to Cost of sales of inventory related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used.

[5] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the second quarter and first six months of 2022 included, among other items, net losses on equity securities of $539 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net. See Note 4.

[6] See Note 1A in our 2022 Form 10-K for information about our recent organizational changes within Biopharma. See Note 13A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.